Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Quantisnow

Ocular Therapeutix will present its 2025 strategic outlook at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.

Ocugen, Inc. reported its Q3 2024 earnings, emphasizing significant advancements in its gene therapy programs, particularly for retinitis pigmentosa and other eye diseases. Despite a slight stock price decline, the company is making strides in clinical trials, including expansion into Canada and FDA approval for an expanded access program. Financials show a cash position of $39 million and operating expenses of $14.4 million, with a recent $30 million debt financing extending the company's runway into Q1 2026.

OS Therapies (NYSE-A: OSTX) will present updates from their Phase 2b trial of OST-HER2 for recurrent osteosarcoma at the upcoming JP Morgan Healthcare Conference. The company anticipates potential FDA approval in 2025, which could earn them a Priority Review Voucher worth approximately $150 million, enabling expansion into other HER2-positive cancers.

Ocugen's OCU400 gene therapy demonstrated a statistically significant improvement in low-luminance visual acuity in patients with retinitis pigmentosa (RP).

Opus Genetics will share detailed 6-month efficacy and safety data on OPGx-LCA5, a gene therapy for LCA5-associated inherited retinal disease, at a virtual KOL event.

Karyopharm Therapeutics announced a favorable study design update for its pivotal Phase 3 SENTRY trial evaluating selinexor in JAKi-naive myelofibrosis patients.

Ocugen will present updates on the Phase 3 liMeliGhT trial for retinitis pigmentosa and new Phase 1/2 data on November 12.

Ocugen will present updates from the Phase 3 liMeliGhT trial for retinitis pigmentosa and new data from Phase 1/2 trials on November 12, 2024.

Oncodesign Precision Medicine presented Phase 1 clinical trial results for OPM-101, a RIPK2 kinase inhibitor, at UEG Week 2024, showcasing its safety profile.

Ocugen's CEO, Dr. Shankar Musunuri, presented the company's modifier gene therapy platform at the 2024 Cell & Gene Meeting on the Mesa.